Roman Pfister
Overview
Explore the profile of Roman Pfister including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
244
Citations
3441
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wrobel J, Kirchner J, Friedrichs K, Gietzen T, Althoff J, Hasse C, et al.
Clin Res Cardiol
. 2025 Mar;
PMID: 40063122
Background: Transtricuspid cardiac implantable electronic devices (CIEDs) complicate the management of tricuspid regurgitation (TR). Transcatheter tricuspid valve annuloplasty (TTVA) offers a promising approach due to minimal interaction with leaflets and...
2.
Kalkan A, Pennig L, Pfister R, Cornely O, Stemler J
Eur Heart J Case Rep
. 2025 Mar;
9(3):ytaf044.
PMID: 40061103
Background: Midostaurin is a multikinase inhibitor for the treatment of Fms-like tyrosine 3 ()-mutated acute myeloid leukaemia (AML). Cardiac adverse events like QTc-prolongation, pericardial effusion, and congestive heart failure have...
3.
Outpatient diuretic intensification: a simple prognostic marker in cardiac transthyretin amyloidosis
Nies R, Ney S, Nies J, Seuthe K, Klosges L, Bruwer M, et al.
Clin Res Cardiol
. 2025 Mar;
PMID: 40035810
Background: Currently, simple clinical parameters indicating disease progression are lacking in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). This study aimed to evaluate the prognostic value of outpatient diuretic intensification (ODI)...
4.
Stolz L, Kalbacher D, Koell B, Karam N, Puscas T, Metra M, et al.
Clin Res Cardiol
. 2025 Feb;
PMID: 39909890
No abstract available.
5.
Schipper J, Sommer A, Nies R, Metze C, Meertens M, Wormann J, et al.
J Am Heart Assoc
. 2025 Feb;
14(3):e038834.
PMID: 39895535
Background: Mitral valve transcatheter edge-to-edge repair (M-TEER) has emerged as a viable therapy option in patients with severe mitral regurgitation and high surgical risk. Although atrial fibrillation is common among...
6.
Fortmeier V, Lachmann M, Stolz L, von Stein J, Rommel K, Kassar M, et al.
JACC Adv
. 2025 Jan;
4(2):101575.
PMID: 39848099
Background: Patients with severe tricuspid regurgitation (TR) typically present with heterogeneity in the extent of cardiac dysfunction and extra-cardiac comorbidities, which play a decisive role for survival after transcatheter tricuspid...
7.
Spieker M, Sidabras J, Lagarden H, Christian L, Gunther N, Angendohr S, et al.
ESC Heart Fail
. 2025 Jan;
PMID: 39829434
Aims: Ischaemic mitral regurgitation (MR) is a dynamic condition influenced by global and regional left ventricular remodelling as well as mitral valvular deformation. Exercise testing plays a substantial role in...
8.
von Stein P, Stolz L, Haurand J, Groger M, Rudolph F, Mustafa D, et al.
JACC Cardiovasc Interv
. 2025 Jan;
18(5):573-586.
PMID: 39745410
Background: The PASCAL P10 system for mitral valve transcatheter edge-to-edge repair has undergone iterations, including introduction of the narrower Ace implant and the Precision delivery system. Objectives: This study sought...
9.
Seuthe K, Pfister R, Pennig L, Mons U, Klingel K, Freyhaus H
Clin Res Cardiol
. 2024 Nov;
PMID: 39570399
Background: In the past decades, cardiovascular magnetic resonance (CMR) was established as a non-invasive tool supporting the diagnosis of myocarditis and there is often reluctance in performing EMB due to...
10.
Stocker T, Stolz L, Karam N, Kalbacher D, Koell B, Trenkwalder T, et al.
JACC Cardiovasc Interv
. 2024 Nov;
17(21):2543-2554.
PMID: 39537275
Background: Mitral valve transcatheter edge-to-edge repair (M-TEER) reduces secondary mitral regurgitation (MR) in heart failure and impacts survival in selected patients as demonstrated in the COAPT (Cardiovascular Outcomes Assessment of...